REMSleep Holdings Inc. has announced the passing of founder Thomas Wood and the appointment of Jeffrey Marshall as Chief Executive Officer, marking a pivotal leadership transition for the medical device company. Wood, who founded REMSleep and served as Chairman and CEO, passed away on February 26, 2026, after dedicating his career to developing sleep apnea solutions, securing 26 patents for CPAP interface components beginning in 1981. His work culminated in the formation of REMSleep and the development of the DeltaWave Nasal Pillow System, which has received FDA 510(k) clearance and PDAC coding approval enabling Medicare reimbursement.
"Tom was more than a founder, he was a visionary and patient advocate who believed that sleep apnea patients deserved better options," said Anita Michaels, who has been elected Chairman of the Board. Wood had worked in recent months with Michaels, his sister and the company's COO, and incoming CEO Marshall to prepare for this transition, ensuring the company had the necessary people, systems, and strategy in place. The Board of Directors has been reconstituted with Michaels as Chairman, Marshall as CEO and Director, and Alexander Johnson appointed as Director, bringing expertise in corporate restructuring and capital markets.
Marshall, who has served as a strategy consultant to REMSleep since September 2025, emphasized the company's readiness for commercial execution. "Tom built the foundation achieving FDA clearance, Medicare approval, and a differentiated product. Now it's our job to execute the commercial opportunity he created," Marshall stated. He outlined immediate priorities including driving sales through strategic marketing plans and building partnerships with Durable Medical Equipment providers, physicians, and sleep labs. The company's flagship product, the DeltaWave Nasal Pillow System, is now commercially available, with management viewing it as the first in a broader portfolio of solutions based on Wood's patented technologies.
Beyond sleep apnea, Wood envisioned applying the same engineering principles to help patients with other chronic respiratory and neurological diseases, a vision now incorporated into the company's strategic roadmap. "Tom's passing is a profound loss, but his work is far from finished," Michaels added. "We have a responsibility to our shareholders, to sleep apnea patients, and to Tom's memory to see this through." The leadership transition plan, including Board formation and CEO appointment, was in process prior to Wood's passing, positioning the company for continued growth and commercialization of its sleep apnea treatment solutions. For more information, visit https://www.remsleep.com.
